Vaccibody demonstrates promising pre-clinical data with its second-generation
COVID-19 vaccine candidate, VB10.COV2

	VB10.COV2 induces rapid, strong and long-lasting neutralizing antibodies and
multifunctional, dominant CD8+ T cell and Th1 CD4+ T cell responses in mice
after a single dose

	Vaccibody will present the pre-clinical data and its broader infectious
disease strategy during a webcast on Friday December 11 at 10 am CET


Oslo, Norway, December 10, 2020 - Today, Vaccibody AS, a clinical-stage
biopharmaceutical company dedicated to the discovery and development of novel
vaccines and immunotherapies, published promising pre-clinical data with its
COVID-19 vaccine candidate, VB10.COV2, in mice. The manuscript describing these
preclinical data is available on the preprint server bioRxiv (see below for
relevant link).

President & Chief Scientific Officer of Vaccibody, Agnete Fredriksen said:
"Vaccibody announced the initiation of its expansion into infectious diseases in
April 2020. Based on preclinical data with a number of pathogens we expected the
platform technology was well suited for developing vaccines against pathogens
with pandemic potential. We are very excited about the supportive data generated
with VB10.COV2 and look forward to explore further the potential of this second
generation COVID-19 vaccine and to use the same platform for other infectious
diseases with high unmet needs."

The SARS-CoV-2 virus has caused over 62 million cases of COVID-19 disease and
over 1.5 million deaths. A safe and effective vaccine able to prevent
transmission and provide persistent protection from the disease is a cornerstone
in the global strategy to mitigate this pandemic. An ideal vaccine, as described
by WHO, would be given as a single dose regimen, ensuring persistent protection
in all age groups through the generation of rapid and long-lasting neutralizing
antibodies and a balanced CD4+ and CD8+ T cells response. Ideally, the vaccine
would be developed on a platform enabling rapid adaptation to antigen changes,
be easy to manufacture at large scale, and be stable at +2-8°C.

Director Infectious Diseases, Gunnstein Norheim commented: "We believe
Vaccibody's innovative vaccine candidate has the potential to address unmet
needs as outlined by the WHO's target product profile for vaccines against
COVID-19. Our preclinical data support a rapid onset of both neutralizing
antibody and T cell immunity after one dose which last for at least three
months. The added multifunctional, dominant CD8+ T cell and Th1 CD4+ T cell
responses offer a broad immune response profile which may provide optimal
protection against COVID-19 disease. This, in combination with the simplicity in
manufacturing and stability of DNA vaccines, substantiate the potential
VB10.COV2 to serve as a second generation COVID-19 vaccine candidate. The
ongoing development efforts and the knowledge we acquire will also support
Vaccibody's more comprehensive efforts to establish a Disease X platform to more
quickly respond to future threats from emerging pathogens."

The article entitled, "Single dose immunization with a COVID-19 DNA vaccine
encoding a chimeric homodimeric protein targeting receptor binding domain (RBD)
to antigen-presenting cells induces rapid, strong and long-lasting neutralizing
IgG, Th1 dominated CD4+ T cells and strong CD8+ T cell responses in mice", has
been published at the bioRxiv preprint server and may be found under the
following link:
https://www.biorxiv.org/content/10.1101/2020.12.08.416875v1.


Webcast
Michael Engsig, CEO